Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $234,261,060 | $236,719,830 | $231,768,733 | $195,872,360 |
| - Cash | $7,511,000 | $6,951,000 | $6,532,000 | $7,616,000 |
| + Debt | $12,941,000 | $13,437,000 | $13,242,000 | $15,275,000 |
| Enterprise Value | $239,691,060 | $243,205,830 | $238,478,733 | $203,531,360 |
| Revenue | $11,369,000 | $11,142,000 | $10,358,000 | $10,974,000 |
| % Growth | 2% | 7.6% | -5.6% | – |
| Gross Profit | $6,338,000 | $6,288,000 | $5,444,000 | $5,598,000 |
| % Margin | 55.7% | 56.4% | 52.6% | 51% |
| EBITDA | $3,015,000 | $3,048,000 | $2,668,000 | $2,989,000 |
| % Margin | 26.5% | 27.4% | 25.8% | 27.2% |
| Net Income | $1,644,000 | $1,779,000 | $1,325,000 | $9,229,000 |
| % Margin | 14.5% | 16% | 12.8% | 84.1% |
| EPS Diluted | 0.94 | 1.01 | 0.758 | 5.27 |
| % Growth | -6.9% | 33.2% | -85.6% | – |
| Operating Cash Flow | $2,787,000 | $2,047,000 | $1,417,000 | $2,868,000 |
| Capital Expenditures | -$496,000 | -$502,000 | -$484,000 | -$720,000 |
| Free Cash Flow | $2,291,000 | $1,545,000 | $933,000 | $2,148,000 |